LifeMD Lands Exclusive Deal for XYOSTED Testosterone Program, Targeting Millions of Men
LFMD sits 91% above its 52-week low of $2.56.
Summary
LifeMD announced an exclusive co-marketing collaboration with Halozyme's Antares Pharma to launch a direct-to-patient self-pay program for XYOSTED (testosterone enanthate) injection. This program, launching in July 2026 across 37 states, makes LifeMD the exclusive telehealth partner and preferred dispensing pharmacy for the FDA-approved once-weekly testosterone auto-injector. The initiative targets millions of men with hypogonadism, offering a transparent $249/month price for medication and care, which could significantly boost LifeMD's subscriber base and revenue. This strategic partnership comes after LifeMD reported a wider net loss and a debt covenant breach in Q1 2026, making new revenue streams particularly important. The program's launch in July will be a key event to watch.
At the time of this announcement, LFMD was trading at $4.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $229.7M. The 52-week trading range was $2.56 to $15.84. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.